Rhapsido: Dosage Form, Projected Sales, NCE-1 Date | Remibrutinib

Rhapsido

Rhapsido is an oral BTK inhibitor indicated for chronic spontaneous urticaria (CSU). By blocking mast cell activation and histamine release, it effectively reduces hives and itch in patients unresponsive to antihistamines.

The information outlined in the molecule details section below would help you evaluate Para IV filing opportunities early to secure a first-to-file advantage.

Molecule Details :

Molecule Name :

Remibrutinib
Innovator :

NOVARTIS PHARMS CORP
Approval Date :

30-Sep-25
NCE-1 Date :

30-Sep-29
NCE Date :

30-Sep-30
Dosage Form :

Oral Tablet
Strength :

25MG
Therapeutic Category :

Immunomodulators
Revenue ($M) :

NA

Year-wise Projected Sales ($M) :

2025 :

29
2026 :

238
2027 :

554
2028 :

934
2029 :

1,293
2030 :

1,636
2031 :

1,931

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Supported 1000+ clinical trials globally
Provides services across regulatory, legal & clinical research
Unmatched intelligence on batches, expiry, spacing, and historical data from innovators
Integrated CRO services as part of our offerings
Insights on global pricing for smarter clinical trial supply decisions
Global sourcing capability across US, EU, South Africa, Canada, Japan, Australia, New Zealand, Southeast Asia, and other key markets

Rhapsido

Molecule Details :

Year-wise Projected Sales ($M) :

Looking for this molecule for your next clinical research? Access regulatory-compliant comparators with assured timelines—delivered reliably through our global network.

Why Partner With Us

Login With

Are you sure want to logout from NCE Grid?